- Trials with a EudraCT protocol (242)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (20)
242 result(s) found for: Case report form.
Displaying page 7 of 13.
EudraCT Number: 2022-001654-38 | Sponsor Protocol Number: TAK-861-2001 | Start Date*: 2023-05-26 | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy With Cataplexy (Narcolepsy Type 1) | |||||||||||||
Medical condition: Narcolepsy with cataplexy (Narcolepsy Type 1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) NO (Completed) FI (Completed) SE (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004482-18 | Sponsor Protocol Number: R076477-SCH-4013 | Start Date*: 2008-01-03 | |||||||||||
Sponsor Name:Ortho-McNeil Janssen Scientific Affairs, LLC | |||||||||||||
Full Title: A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone. | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005905-23 | Sponsor Protocol Number: M10-261 | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Abbott GmbH & Co. KG | |||||||||||||
Full Title: A Multi-center, Randomized, Double-blind, Placebo − controlled Study Comparing 80 mg of Adalimumab with Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared Wi... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001087-10 | Sponsor Protocol Number: ELA-0121 | Start Date*: 2022-11-21 | |||||||||||
Sponsor Name:Stemline Therapeutics, Inc | |||||||||||||
Full Title: An Open-label Multicenter Phase 1b-2 Study of Elacestrant as Monotherapy and in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative B... | |||||||||||||
Medical condition: Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) IT (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002227-13 | Sponsor Protocol Number: ACP-103-045 | Start Date*: 2018-02-04 | ||||||||||||||||
Sponsor Name:ACADIA Pharmaceuticals Inc. | ||||||||||||||||||
Full Title: A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis | ||||||||||||||||||
Medical condition: Hallucinations and Delusions Associated With Dementia-related Psychosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) SK (Prematurely Ended) BG (Completed) ES (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005510-34 | Sponsor Protocol Number: MMV_DSM265_14_01 | Start Date*: 2015-09-30 | |||||||||||
Sponsor Name:Medicines for Malaria Venture | |||||||||||||
Full Title: Evaluation of the prophylactic antimalarial activity of a single dose of DSM265 in non-immune healthy adult volunteers by controlled human malaria infection with PfSPZ Challenge | |||||||||||||
Medical condition: Healthy volunteers; controlled human malaria infection with PfSPZ | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004367-20 | Sponsor Protocol Number: MET54 | Start Date*: 2015-03-16 | ||||||||||||||||
Sponsor Name:Sanofi Pasteur | ||||||||||||||||||
Full Title: A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccines in Healthy Toddlers | ||||||||||||||||||
Medical condition: Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y or W) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000385-35 | Sponsor Protocol Number: RA0069 | Start Date*: 2011-08-19 | |||||||||||
Sponsor Name:UCB PHARMA | |||||||||||||
Full Title: MULTICENTER, OPEN LABEL STUDY TO EVALUATE THE PREDICTABILITY OF EARLY RESPONSE TO CERTOLIZUMAB PEGOL (IN COMBINATION WITH METHOTREXATE) AS CONFIRMED AT WEEK 52 IN SUBJECTS WITH MODERATE-SEVERE RHEU... | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003267-55 | Sponsor Protocol Number: A3L45 | Start Date*: 2015-09-03 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur SA | ||||||||||||||||||||||||||||
Full Title: An international, multicenter, open-label, one-arm study in 150 infants vaccinated with a 3-dose primary series of the DTaP-IPV-Hep B-PRP-T combined vaccine in the Russian Federation and Poland. | ||||||||||||||||||||||||||||
Medical condition: Prevention of infections caused by Corynebacterium diphtheriae, Clostridium tetani, Bordetella pertussis, poliovirus type 1, 2 and 3, prevention against invasive infections caused by Haemophilus in... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-002452-40 | Sponsor Protocol Number: Td500056 | Start Date*: 2023-03-08 | ||||||||||||||||||||||||||
Sponsor Name:Sanofi Pasteur | ||||||||||||||||||||||||||||
Full Title: Immune Response to Pertussis after Vaccination with a Tdap-IPV Booster Vaccine in Children in the Republic of South Africa: Effect of Homologous and Heterologous Pertussis Vaccination Priming Backg... | ||||||||||||||||||||||||||||
Medical condition: Bacterial infections | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002498-36 | Sponsor Protocol Number: CCN017 | Start Date*: 2018-10-12 | |||||||||||
Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | |||||||||||||
Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception | |||||||||||||
Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015579-28 | Sponsor Protocol Number: FER-CKD-01 | Start Date*: 2009-12-22 | ||||||||||||||||
Sponsor Name:Vifor Pharma Inc. | ||||||||||||||||||
Full Title: An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject® High- and Low-dosage Regimens) versus Oral Ir... | ||||||||||||||||||
Medical condition: Iron deficiency anaemia in subjects with non-dialysis-dependent chronic kidney disease | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) BE (Completed) SE (Completed) FR (Completed) DE (Completed) DK (Completed) ES (Completed) IT (Completed) CZ (Completed) AT (Completed) GR (Completed) PT (Completed) NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001132-22 | Sponsor Protocol Number: BGB-A317-NSCL-001 | Start Date*: 2019-05-20 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects with Locally A... | ||||||||||||||||||||||||||||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: PT (Completed) ES (Prematurely Ended) FI (Prematurely Ended) PL (Completed) HU (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-021143-41 | Sponsor Protocol Number: 31-10-270 | Start Date*: 2010-12-22 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Patients with Schizophrenia | |||||||||||||
Medical condition: Schizophrenia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) BG (Completed) SK (Completed) HU (Completed) EE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001673-75 | Sponsor Protocol Number: ABX464-401 | Start Date*: 2020-05-06 |
Sponsor Name:ABIVAX | ||
Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu... | ||
Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000675-20 | Sponsor Protocol Number: ISIS766720-CS5 | Start Date*: 2020-11-04 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open Label, Randomized, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor, Administered Monthly as Monotherap... | |||||||||||||
Medical condition: Acromegaly is a chronic disorder caused by GH hypersecretion, most commonly as a result of a GH-secreting pituitary adenoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) LT (Completed) PL (Completed) LV (Prematurely Ended) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004764-39 | Sponsor Protocol Number: CTBM100C2303E1 | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Comp... | |||||||||||||
Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004567-21 | Sponsor Protocol Number: 3119001 | Start Date*: 2015-06-05 | |||||||||||
Sponsor Name:Orion Corporation Orion Pharma | |||||||||||||
Full Title: Effects of ODM-109 on respiratory function in patients with ALS. A randomised, double blind, placebo-controlled, cross-over, 3-period, multicentre study with open-label follow-up extension | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS). A rapidly progressive neurological disease characterized by degeneration of upper and lower motor neurons with subsequent muscle atrophy and weakness and loss ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001835-35 | Sponsor Protocol Number: 2014.TTRANSPORT | Start Date*: 2015-03-30 | |||||||||||
Sponsor Name:Fundación Santiago Dexeus Font (Dexeus) | |||||||||||||
Full Title: Transdermal testosterone gel for poor ovarian responders. A multicenter double-blind placebo controlled randomized trial. | |||||||||||||
Medical condition: Infertility in women with poor ovarian response to stimulation for IVF/ICSI | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) ES (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006538-16 | Sponsor Protocol Number: A6181114 | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US | |||||||||||||
Full Title: AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNI... | |||||||||||||
Medical condition: Malignant Gastrointestinal Stromal Tumor (GIST), Metastatic Breast Cancer, Metastatic Renal Cell Cancer, Pancreatic Neuroendocrine Tumor, Hepatocellular Carcinoma, Prostate Cancer, Thyroid Cancer, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) FR (Completed) DK (Prematurely Ended) GB (Completed) NL (Prematurely Ended) BG (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
